NVCR vs. LMAT, ATRC, MDXG, ATEC, AORT, FNA, SILK, ATRI, KIDS, and TMCI
Should you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include LeMaitre Vascular (LMAT), AtriCure (ATRC), MiMedx Group (MDXG), Alphatec (ATEC), Artivion (AORT), Paragon 28 (FNA), Silk Road Medical (SILK), Atrion (ATRI), OrthoPediatrics (KIDS), and Treace Medical Concepts (TMCI). These companies are all part of the "surgical & medical instruments" industry.
LeMaitre Vascular (NASDAQ:LMAT) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, community ranking, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.
84.6% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 10.8% of LeMaitre Vascular shares are owned by insiders. Comparatively, 5.7% of NovoCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
LeMaitre Vascular received 34 more outperform votes than NovoCure when rated by MarketBeat users. Likewise, 70.96% of users gave LeMaitre Vascular an outperform vote while only 63.71% of users gave NovoCure an outperform vote.
LeMaitre Vascular has a net margin of 16.99% compared to LeMaitre Vascular's net margin of -36.67%. NovoCure's return on equity of 11.57% beat LeMaitre Vascular's return on equity.
LeMaitre Vascular has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500.
In the previous week, LeMaitre Vascular had 15 more articles in the media than NovoCure. MarketBeat recorded 33 mentions for LeMaitre Vascular and 18 mentions for NovoCure. NovoCure's average media sentiment score of 0.53 beat LeMaitre Vascular's score of 0.06 indicating that LeMaitre Vascular is being referred to more favorably in the media.
LeMaitre Vascular currently has a consensus price target of $73.83, suggesting a potential downside of 2.72%. NovoCure has a consensus price target of $30.88, suggesting a potential upside of 98.81%. Given LeMaitre Vascular's higher possible upside, analysts plainly believe NovoCure is more favorable than LeMaitre Vascular.
LeMaitre Vascular has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.
Summary
LeMaitre Vascular beats NovoCure on 15 of the 17 factors compared between the two stocks.
Get NovoCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovoCure Competitors List
Related Companies and Tools
